BMB18 clinical trial expands to dual site

• Multi-centre clinical trial for BMB18 initiated in Australia and Greece
• Three-arm study evaluates two dosage levels of BMB18
• Athens site led by Professor George Moschonis
• Recruitment starts within previously disclosed timeline

Biome Australia Ltd. has expanded its BMB18 clinical trial to include a second site at Harokopio University of Athens, led by Professor George Moschonis. This multi-centre trial, which also includes La Trobe University in Melbourne, is a three-arm, double-blind, placebo-controlled study evaluating two dosage levels of BMB18 against a placebo. The trial will involve 240 participants over a six-week intervention period, followed by a two-week post-intervention follow-up. Recruitment has begun this week, in line with the previously disclosed Q4 FY26 timeline.